{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:48:19Z","timestamp":1790995699350,"version":"4.1.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2026,7]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n \n Inclisiran for LDL cholesterol reduction was analyzed\n post hoc<\/jats:italic>\n in patients with CKD.\n <\/jats:p>\n <\/jats:list-item>\n \n Mean percentage LDL cholesterol reduction from baseline was around 50% regardless of eGFR in phase 3 trials.<\/jats:p>\n <\/jats:list-item>\n \n Inclisiran showed sustained and effective LDL cholesterol\u2013lowering in patients across various levels of eGFR values, without new safety findings.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n \n Lowering LDL cholesterol reduces the risk of atherosclerotic cardiovascular disease in patients with CKD. The efficacy and safety of inclisiran versus placebo in patients without and with CKD were investigated in a\n post hoc<\/jats:italic>\n pooled analysis of three phase 3 trials (ORION-9, ORION-10, and ORION-11).\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Patients with heterozygous familial hypercholesterolemia, atherosclerotic cardiovascular disease or its risk equivalent, and elevated LDL cholesterol were randomized 1:1 to subcutaneous inclisiran or placebo on days 1 and 90 and every 6 months thereafter for 540 days. Patients were stratified based on baseline eGFR (by CKD Epidemiology Collaboration equation): \u226590, 60 to <90, 45 to <60, and 15 to <45 ml\/min per 1.73 m\n 2<\/jats:sup>\n . Coprimary end points were percentage change in LDL cholesterol at day 510 and time-adjusted percentage change after day 90 and through day 540. Safety was also evaluated.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 3660 patients, 1610 (44%) had eGFR \u226590, 1608 (44%) 60 to <90, 300 (8%) 45 to <60, and 142 (4%) 15 to <45 ml\/min per 1.73 m\n 2<\/jats:sup>\n . The mean (95% confidence interval) placebo-corrected percentage changes in LDL cholesterol from baseline at day 510 in patients with eGFR \u226590, 60 to <90, 45 to <60, and 15 to <45 ml\/min per 1.73 m\n 2<\/jats:sup>\n were \u221249.9% (\u221253.2 to \u221246.6), \u221251.2% (\u221254.4 to \u221248.0), \u221254.7% (\u221262.5 to \u221247.0), and \u221244.7% (\u221257.6 to \u221231.8), respectively (\n P<\/jats:italic>\n < 0.001); the corresponding mean (95% confidence interval) time-adjusted placebo-corrected percentage changes in LDL cholesterol from baseline after day 90 through day 540 were \u221248.4% (\u221250.8 to \u221246.1), \u221251.8% (\u221254.2 to \u221249.4), \u221255.6% (\u221261.0 to \u221250.2), and \u221250.4% (\u221259.3 to \u221241.5; each\n P<\/jats:italic>\n < 0.001). Significant decreases in total cholesterol, apolipoprotein B, non-HDL cholesterol, and lipoprotein(a) occurred in all eGFR groups. Inclisiran was well tolerated without new safety findings.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Inclisiran demonstrated sustained and effective LDL cholesterol reduction in patients with or at risk of atherosclerotic cardiovascular disease, regardless of baseline eGFR as low as 15 ml\/min per 1.73 m\n 2<\/jats:sup>\n , without new safety findings.\n <\/jats:p>\n <\/jats:sec>\n \n Clinical Trial registry name and registration number:<\/jats:title>\n ClinicalTrials.gov, ORION-9 (NCT03397121), ORION-10 (NCT03399370), and ORION-11 (NCT03400800).<\/jats:p>\n <\/jats:sec>","DOI":"10.1681\/asn.0000001006","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T17:00:33Z","timestamp":1769619633000},"page":"1497-1506","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Inclisiran in Patients with CKD"],"prefix":"10.1681","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0214-3203","authenticated-orcid":false,"given":"Ulf","family":"Landmesser","sequence":"first","affiliation":[{"name":"Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charit\u00e9, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin Institute of Health, DZHK, Partner Site Berlin, Friede Springer Cardiovascular Prevention Center at Charit\u00e9, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0508-0954","authenticated-orcid":false,"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[{"name":"Department of Primary Care and Public Health, Imperial Centre for Cardiovascular Disease Prevention, Imperial College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9170-7938","authenticated-orcid":false,"given":"Frederick J.","family":"Raal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Garcia Conde","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Han","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-9603","authenticated-orcid":false,"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[{"name":"German Heart Centre, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Munich, Germany"},{"name":"DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany"},{"name":"Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1040-6229","authenticated-orcid":false,"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[{"name":"Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2954-0695","authenticated-orcid":false,"given":"Gregory G.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0625-0444","authenticated-orcid":false,"given":"R. Scott","family":"Wright","sequence":"additional","affiliation":[{"name":"Division of Preventive Cardiology, Department of Cardiology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ORION Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"25","key":"B1-20260826","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"11","key":"B2-20260826","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation."},{"issue":"7","key":"B3-20260826","doi-asserted-by":"crossref","first-page":"563","DOI":"10.7326\/0003-4819-137-7-200210010-00007","article-title":"Acute myocardial infarction and renal dysfunction: a high-risk combination","volume":"137","author":"Wright","year":"2002","journal-title":"Ann Intern Med."},{"issue":"6","key":"B4-20260826","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","article-title":"Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease","volume":"93","author":"Toth","year":"2018","journal-title":"Kidney Int."},{"issue":"25","key":"B5-20260826","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med."},{"issue":"4","key":"B6-20260826","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int."},{"issue":"34","key":"B7-20260826","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC)","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J."},{"issue":"3","key":"B8-20260826","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40620-020-00707-2","article-title":"Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology","volume":"33","author":"Pontremoli","year":"2020","journal-title":"J Nephrol."},{"issue":"suppl 2","key":"B9-20260826","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.2337\/dcS13-2038","article-title":"Intolerance to statins: mechanisms and management","volume":"36","author":"Bitzur","year":"2013","journal-title":"Diabetes Care."},{"issue":"23","key":"B10-20260826","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol."},{"issue":"42","key":"B11-20260826","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1093\/eurheartj\/ehaa498","article-title":"Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial","volume":"41","author":"Tu\u00f1\u00f3n","year":"2020","journal-title":"Eur Heart J."},{"issue":"10","key":"B12-20260826","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1681\/ASN.2016090957","article-title":"Benefit of ezetimibe added to simvastatin in reduced kidney function","volume":"28","author":"Stanifer","year":"2017","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B13-20260826","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12933-023-01752-4","article-title":"Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease","volume":"22","author":"Nishikido","year":"2023","journal-title":"Cardiovasc Diabetol."},{"issue":"16","key":"B14-20260826","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"New Engl J Med."},{"issue":"16","key":"B15-20260826","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"New Engl J Med."},{"issue":"9","key":"B16-20260826","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"B17-20260826","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies","volume":"95","author":"Wright","year":"2020","journal-title":"Mayo Clin Proc."},{"issue":"19","key":"B18-20260826","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New Creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"New Engl J Med."},{"issue":"6","key":"B19-20260826","first-page":"18","article-title":"Emerging therapies for cardiovascular disease: PCSK9 inhibitors and their potential role in patients with CKD","volume":"12","author":"Elsadany","year":"2020","journal-title":"Kidney News"},{"issue":"1","key":"B20-20260826","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J."},{"issue":"4","key":"B21-20260826","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein (a) in chronic kidney disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J Lipid Res."},{"issue":"25","key":"B22-20260826","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.jacc.2008.03.025","article-title":"Managing dyslipidemia in chronic kidney disease","volume":"51","author":"Harper","year":"2008","journal-title":"J Am Coll Cardiol."},{"issue":"7","key":"B23-20260826","doi-asserted-by":"crossref","first-page":"e0132970","DOI":"10.1371\/journal.pone.0132970","article-title":"Effects of statins on renal outcome in chronic kidney disease patients: a systematic review and meta-analysis","volume":"10","author":"Sanguankeo","year":"2015","journal-title":"PLoS One."},{"issue":"24","key":"B24-20260826","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","article-title":"Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials","volume":"82","author":"Wright","year":"2023","journal-title":"J Am Coll Cardiol."},{"issue":"12","key":"B25-20260826","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","article-title":"Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial","volume":"120","author":"Wright","year":"2024","journal-title":"Cardiovasc Res."}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:06:15Z","timestamp":1787745975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001006"}},"subtitle":["Post Hoc Pooled Analysis of Three Phase 3 Trials"],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.0000001006","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"2025-09-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}